AMBU B Ambu A/S Class B

Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities

Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.  

The attached document discloses the data of the transactions made in Ambu shares. 

Attachment



EN
09/02/2024

Underlying

AMBU BAmbu A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Free Trial
AMBU B Ambu A/S Class ...

Ambu AS: 2 directors

Two Directors at Ambu AS bought 21,500 shares at between 112.950DKK and 114.090DKK. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

AMBU B AMBU A/S CLASS B
12h / 16m 12h / 16m 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
AMBU B Ambu A/S Class ...

Ambu (Buy, TP: DKK140.00) - Solid guidance considering soft Q4

We view the 2024/25 guidance as solid given the Q4 miss and management’s conservative tendency. Pulmonology growth might be below our forecast for 2024/25, but the strong momentum in the rest of Endoscopy should make up for it. We view the investment case as intact, and thus reiterate our BUY, but have cut our target price to DKK140 (145) on the Q4 margin miss.

AMBU B AMBU A/S CLASS B
11/06/24 November 6, 2024 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
AMBU B AMBU A/S CLASS B
11/05/24 November 5, 2024 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
AMBU B AMBU A/S CLASS B
10/29/24 October 29, 2024 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
AMBU B Ambu A/S Class ...

Ambu (Buy, TP: DKK145.00) - Q4 focus: Pulmonary and guidance

We believe Ambu will report a stronger Q4 than expected by consensus, but ultimately expect focus to be on the Pulmonary growth momentum in the quarter as well as the 2024/25 guidance. We look for guidance of at least 10–13% organic growth, with consensus at the high end, but which we view as probably conservative. We reiterate our BUY and DKK145 target price.

AMBU B AMBU A/S CLASS B
10/15/24 October 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch